1. Neuroscience
Download icon

Alzheimer’s Disease: Identifying faulty brain circuits

  1. Jesse E Hanson  Is a corresponding author
  1. Genentech, Inc., United States
Insight
  • Cited 3
  • Views 1,916
  • Annotations
Cite this article as: eLife 2017;6:e26942 doi: 10.7554/eLife.26942
Voice your concerns about research culture and research communication: Have your say in our 7th annual survey.

Abstract

A protein called NPTX2 may be a useful marker of neural circuit defects in patients with Alzheimer’s disease.

Main text

Individuals with Alzheimer’s disease experience memory loss, and find it difficult to make decisions and learn new things. These cognitive impairments begin in the early stages of the disease and are the result of changes to neurons and the connections between them. Accumulating evidence suggests that these changes involve inhibitory interneurons, which normally shape and restrain the activity of circuits of neurons, becoming less active (Palop and Mucke, 2016). However, it is not fully understood what causes the loss of interneuron activity in Alzheimer’s disease. Furthermore, it is hard to identify if interneurons have been affected in specific patients because there are currently no known molecular biomarkers of interneuron activity.

Now, in eLife, Paul Worley from the Johns Hopkins University School of Medicine and co-workers – including Mei-Fang Xiao and Desheng Xu as joint first authors – report that the loss of a protein called NPTX2 disrupts interneuron-mediated circuit activity in Alzheimer’s disease (Xiao et al., 2017). They also put forward NPTX2 as a biomarker that could be used to measure defects in neural circuits seen in patients with the disease.

NPTX2 (also known as NARP) is released from excitatory neurons and binds to receptors on interneurons that are characterized by the expression of another protein called parvalbumin (Chang et al., 2010). These receptors, known as AMPA receptors, activate the neurons; thus NPTX2 is important in maintaining the normal activity of the parvalbumin interneurons, which prevents certain neural circuits from becoming too active (Gu et al., 2013). Xiao et al. found that patients with Alzheimer’s disease have less NPTX2 in their brains compared to healthy individuals (Figure 1). The brains of these patients also have lower levels of a subunit of the AMPA receptors called GluA4 (which is preferentially expressed in parvalbumin interneurons).

Parvalbumin interneurons in Alzheimer’s disease.

Parvalbumin interneurons (PV interneuron) connect to excitatory neurons in the forebrain (top). In healthy individuals (control; left), the NPTX2 protein (red) arranges GluA4-containing AMPA receptors (blue) in clusters at these connections. As a result, electrical signals from the excitatory neurons strongly activate the interneurons. A sodium channel called Nav1.1 (black) in the interneurons helps to generate electrical signals that inhibit other neurons in the circuit. In the brains of individuals with Alzheimer’s disease (right), the levels of NPTX2, GluA4 and Nav1.1 are all lower than in healthy individuals; this leads to less inhibitory interneuron activity. Other neurons in the circuit thus become more active than they should be, resulting in defects in circuit function and cognitive impairments. NPTX2 can also be detected in the cerebrospinal fluid (CSF; bottom). Individuals with Alzheimer’s disease (right) have less NPTX2 in their CSF compared to healthy individuals (control; left). NPTX2 levels in CSF correlate with cognitive impairments.

IMAGE CREDIT: JE Hanson, A Bruce.

A fundamental feature of Alzheimer’s disease is the accumulation of a peptide called amyloid beta in the brain in a process called amyloidosis. To explore how NPTX2 might be interacting with amyloidosis, Xiao et al. turned to mouse models. They found that mice with amyloidosis and deletion of the NPTX2 gene had lower levels of GluA4 and more defects in circuit activity than mice with just amyloidosis alone. Xiao et al. also observed that humans with amyloidosis, but not Alzheimer’s disease, have normal levels of NPTX2 in their brain. Together these results support the idea that amyloidosis does not immediately cause a decrease in NPTX2 expression, but rather that a drop in NPTX2 could be a “second hit” that collaborates with amyloidosis to lead to the defects in neural circuits and cognition seen in Alzheimer’s disease.

Other observations also support the model in which parvalbumin interneurons being less active causes defects in neural circuits in Alzheimer’s disease. For example, patients with Alzheimer’s disease and mouse models of the disease also have reduced levels of a sodium channel called Nav1.1, which is critical for parvalbumin interneuron activity (Verret et al., 2012). Restoring Nav1.1 to normal levels improves circuit activity and reduces cognitive impairments in the mouse models. A recent study shows that enhancing parvalbumin interneuron activity in a mouse model of Alzheimer’s disease can decrease the accumulation of amyloid peptides in the brain (Iaccarino et al., 2016). These studies suggest that reduced activity of parvalbumin interneurons may contribute to the symptoms and pathology of Alzheimer’s disease.

Xiao et al. next assessed NPTX2 in human cerebrospinal fluid and found reduced levels in Alzheimer’s disease patients (Figure 1). They found that NPTX2 levels performed as well as current biomarkers of the disease in terms of sensitivity and specificity in distinguishing patients from healthy controls. Xiao et al. also found that NPTX2 levels in cerebrospinal fluid correlated with cognitive performance in the patients. This is consistent with another recent study showing that Alzheimer’s disease patients with higher initial levels of NPTX2 in their cerebrospinal fluid experience less memory decline over a two-year period (Swanson and Willette, 2016).

The ability to detect reduced NPTX2 in cerebrospinal fluid is relevant because targeting parvalbumin interneurons in particular, and circuit defects in general, is emerging as a potential way to treat cognitive impairments in patients with Alzheimer’s disease (Palop and Mucke, 2016). For example, an ongoing clinical effort is testing an anticonvulsant drug called levetiracetam as a treatment for cognitive impairment (NCT02002819; Bakker et al., 2012) based on observations in patients (Yassa et al., 2010) and mouse models (Sanchez et al., 2012). Using NPTX2 as a biomarker might help such clinical efforts to identify patients who may have neural circuit defects.

More work is needed to understand the root causes of the decreases in NPTX2 and GluA4 levels in Alzheimer’s disease. Clinical experiments examining brain activity in Alzheimer’s patients would help to confirm that reduced NPTX2 levels are actually associated with neural circuit defects in human patients (and not just mouse models).

References

Article and author information

Author details

  1. Jesse E Hanson

    Department of Neuroscience, Genentech, Inc., San Francisco, United States
    For correspondence
    hanson.jesse@gene.com
    Competing interests
    The author declares that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3059-5132

Publication history

  1. Version of Record published: April 25, 2017 (version 1)

Copyright

© 2017, Hanson

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,916
    Page views
  • 221
    Downloads
  • 3
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Developmental Biology
    2. Neuroscience
    Matthieu Genestine et al.
    Research Article Updated

    Cortical interneurons establish inhibitory microcircuits throughout the neocortex and their dysfunction has been implicated in epilepsy and neuropsychiatric diseases. Developmentally, interneurons migrate from a distal progenitor domain in order to populate the neocortex – a process that occurs at a slower rate in humans than in mice. In this study, we sought to identify factors that regulate the rate of interneuron maturation across the two species. Using embryonic mouse development as a model system, we found that the process of initiating interneuron migration is regulated by blood vessels of the medial ganglionic eminence (MGE), an interneuron progenitor domain. We identified two endothelial cell-derived paracrine factors, SPARC and SerpinE1, that enhance interneuron migration in mouse MGE explants and organotypic cultures. Moreover, pre-treatment of human stem cell-derived interneurons (hSC-interneurons) with SPARC and SerpinE1 prior to transplantation into neonatal mouse cortex enhanced their migration and morphological elaboration in the host cortex. Further, SPARC and SerpinE1-treated hSC-interneurons also exhibited more mature electrophysiological characteristics compared to controls. Overall, our studies suggest a critical role for CNS vasculature in regulating interneuron developmental maturation in both mice and humans.

    1. Neuroscience
    2. Structural Biology and Molecular Biophysics
    Monica L Fernández-Quintero et al.
    Research Article Updated

    Voltage-gated calcium channels control key functions of excitable cells, like synaptic transmission in neurons and the contraction of heart and skeletal muscles. To accomplish such diverse functions, different calcium channels activate at different voltages and with distinct kinetics. To identify the molecular mechanisms governing specific voltage sensing properties, we combined structure modeling, mutagenesis, and electrophysiology to analyze the structures, free energy, and transition kinetics of the activated and resting states of two functionally distinct voltage sensing domains (VSDs) of the eukaryotic calcium channel CaV1.1. Both VSDs displayed the typical features of the sliding helix model; however, they greatly differed in ion-pair formation of the outer gating charges. Specifically, stabilization of the activated state enhanced the voltage dependence of activation, while stabilization of resting states slowed the kinetics. This mechanism provides a mechanistic model explaining how specific ion-pair formation in separate VSDs can realize the characteristic gating properties of voltage-gated cation channels.